Product Description: LXE408 is an orally active, non-competitive and kinetoplastid-selective proteasome inhibitor. LXE408 has an IC50 of 0.04 μM for L. donovani proteasome and an EC50 of 0.04 μM for L. donovani. LXE408 has a low propensity to cross the blood brain barrier. LXE408 has the potential for visceral leishmaniasis (VL) research[1].
Applications: COVID-19-immunoregulation
Formula: C23H18FN7O2
References: [1]Advait Nagle, et al. Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. J Med Chem. 2020 Jul 15.
CAS Number: 1799330-15-6
Molecular Weight: 443.43
Compound Purity: 99.08
Research Area: Infection
Solubility: DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 60°C)